The future of PRAC in cancer treatment looks promising, with ongoing research and clinical trials exploring its use in a broader range of cancers and in combination with other treatments. As our understanding of cancer genetics and DNA repair mechanisms improves, PARP inhibitors are likely to become an integral part of personalized medicine, offering targeted therapies based on individual genetic profiles.
